Physician profile
Ron L Moses
NPI 1467434704
$2,230.43
in general payments reported to CMS, 2019-2025
19 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $126 · 2021: $270 · 2022: $253 · 2023: $171 · 2024: $102 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $800 · Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $800.00 |
| Food and Beverage | $504.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spirair, INC. | $800.00 | 2025 | |
| Optinose US, INC. | $328.06 | 2019-2025 | |
| Acclarent, INC | $220.03 | 2019-2021 | |
| Glaxosmithkline, LLC. | $187.20 | 2023-2025 | Nucala |
| Medtronic, INC. | $146.99 | 2022-2024 | Nuvent, Sinuva |
| Intersect Ent, INC. | $120.27 | 2020-2021 | |
| Aerin Medical INC. | $105.40 | 2021-2023 | |
| Stryker Corporation | $76.17 | 2019-2021 | |
| Kaleo, INC. | $47.98 | 2022-2023 | Auvi-Q |
| Genzyme Corporation | $45.26 | 2022-2023 | |
| Integra Lifesciences Corporation | $22.22 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.68 | 2025 | Tezspire |
| Hikma Pharmaceuticals USA | $19.42 | 2025 | Ryaltris |
| Regeneron Healthcare Solutions, INC. | $16.65 | 2023 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $15.81 | 2025 | Neffy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $15.39 | 2023 | Olympus |
| Inspire Medical Systems, INC. | $15.37 | 2025 | Inspire |
| Arrinex, INC. | $14.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.